PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer
Key facts
- Where
- Angers, Pontoise és Saint-Herblain Cedex, FranciaországSee the 4 sites
- Phase
- 2. fázis
Where in Franciaország
- Centre Hospitalier Universitaire D'AngersAngers, FranciaországNo longer taking part
- Institut de Cancerologie de L'OuestAngers, FranciaországNo longer taking part
- Hôpital NOVOPontoise, FranciaországNo longer taking part
- Institut De Cancerologie De L OuestSaint-Herblain Cedex, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut De Cancerologie De L Ouest
- Trial code
- EU 2024-515850-26-00
- Record updated
- 2024. december 10.
- Original description
To define the sensitivity of PET-DOPA for the detection of newly diagnosed untreated brain metastases (breast, lung, melanoma) on MRI measuring at least 5 mm in diameterRead full original descriptionShow less
PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer (DOPACER)
To define the sensitivity of PET-DOPA for the detection of newly diagnosed untreated brain metastases (breast, lung, melanoma) on MRI measuring at least 5 mm in diameter
Inclusion: Histologically proven primary cancer (non-small cell lung, breast or melanoma); Presence of brain metastasis(s) visualized on MRI, with at least 1 measuring more than 5 mm; Age ≥ 18 years.
Exclusion: Previous brain surgery for brain metastasis or glial tumor; Systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6 weeks preceding the PET-DOPA scan,; New anti-tumor treatment (excluding corticosteroids) started between the discovery of CD and the performance of the PET-DOPA scan; History of cerebral irradiation; Other concomitant cancer, or history of cancer in the 5 years preceding the patient's inclusion in the protocol other than basal or squamous cell carcinoma; Pregnant, likely to be pregnant or breastfeeding.